UK bags Europe’s M&A top spot with $247bn of deals in 2018 as TMT mergers grow The UK enjoyed the highest value of M&A deals in Europe last year as telecoms and media takeovers spiked. High value purchases like Comcast’s $39bn purchase of Sky pushed mergers involving UK companies to $247bn in 2018, data compiled by law firm Clifford Chance found. Read more: Watchdog delays final report on Sainsbury's-Asda merger Both domestic and [...]
Takeda finishes £46bn Shire takeover months ahead of schedule Takeda has completed the takeover of London-listed Shire ahead of schedule after shareholders overwhelmingly backed the controversial $59bn (£46bn) deal last month. The acquisition, which becomes the largest ever for a Japanese company, won 89 per cent approval in December despite a battle over the future of the company. It creates a $30bn pharmaceutical giant [...]
Takeda wins shareholder approval for £46bn Shire takeover Takeda’s investors have approved the company’s $59bn (£46bn) takeover of Irish drugmaker Shire following months of wrangling with unhappy stakeholders. Despite a chorus of unhappy investors who have gone public with their anger about the deal, 88 per cent of shareholders’ votes came down in favour of the proposal, Takeda said this morning. The deal [...]
Big pharma: Takeda sets date for shareholder vote on $62bn Shire merger November 12, 2018 Takeda Pharmaceutical will ask shareholders to vote on buying biotechnology firm Shire for $62bn (£48bn) on 5 December, it revealed today. Takeda hopes to complete the purchase of the Dublin-based company on 8 January after holding the extraordinary general meeting (EGM) with shareholders and gaining approval from the European Commission. “The acquisition of Shire will [...]
Shire looks to lift $30bn bid for rival Baxalta August 16, 2015 Irish drug giant Shire Pharmaceuticals is prepared to top up its offer to woo rival Baxalta to the negotiating table on condition it is given direct access to its books, sources say. Shire made its all-stock $30bn (£19.2bn), or $45 per share, offer last month for US drug maker Baxalta, which has so far [...]
Baxalta hints it will accept a bid from Shire, but only if it offers an extra $5bn August 16, 2015 Shire's attempt to buy Baxalta could prove successful, so long as the pharmaceutical company agrees to add an extra $5bn (£3.2bn) to its original offer. Read more: Shire share price drops following £19bn hostile takeover bid to Baxalta At the beginning of August, Shire made a hostile bid worth an estimated $30bn (£19bn) to [...]
Shire share price rises as investors become optimistic about Baxalta hostile takeover bid August 10, 2015 Shares in pharma giant Shire recovered this morning after its $30bn (£19bn) hostile bid to take over US biotech company Baxalta. Read more: Shire share price drops following £19bn hostile takeover bid to Baxalta The offer by the UK company, which amounts to $45.23 per Baxalta share, followed an unsuccessful attempt to get Baxalta [...]
Shire share price drops following £19bn hostile takeover bid to Baxalta August 10, 2015 London-listed pharma giant Shire has made a hostile approach for US rival Baxalta. In a statement, the UK company offered $45.23 per Baxalta share, amounting to a deal worth an estimated $30bn (£19bn). Baxalta, a biotech business focused on developing treatments for rare diseases, was spun-out of Baxter International last month. Shire [...]
Shire ramps up bid to win over Baxalta board August 10, 2015 The board of Baxalta will come under renewed pressure to open takeover negotiations this week, following early campaigning by Shire to promote its $30bn (£19.4bn) offer for the US firm. However, Baxalta insists that it will not accept this offer, with a company source describing the bid price as being “nowhere near” the value [...]
Shire rebuffed over £12bn move for its listed Swiss rival Actelion June 7, 2015 ADHD drug-maker Shire is looking at a £12.4bn takeover of Europe’s biggest biotech company Actelion – just months after completing another $5bn (£3.3bn) acquisition. The Irish-headquartered firm, which is led by chief executive Flemming Ornskov, approached the listed Swiss company with a proposal for a full-blown takeover but was turned down, despite offering a [...]